Enhancing mTOR-targeted cancer therapy
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The mammalian target of rapamycin (mTOR) has emerged as an attractive cancer therapeutic target. Accordingly, several mTOR inhibitors (e.g., rapamycin and its analogs; rapalogs) are currently being tested in many cancer clinical trials. Despite the encouraging results showing that some rapalogs improved overall survival among patients with metastatic renal-cell carcinoma, the single-agent activity of rapalogs in most other tumor-types has been modest, at best. OBJECTIVE: To review the current understanding of the mTOR axis and discuss potential strategies to enhance mTOR-targeted cancer therapy. METHODS: Preclinical and clinical data in peer-reviewed reports on the novel biological and therapeutic parts of the mTOR axis are discussed. CONCLUSION: The mTOR axis involves complex regulatory networks. Inhibition of the mTOR axis with a rapalog induces feedback activation of several survival signaling pathways such as Akt activation, which, in turn, blunt rapalogs' anticancer efficacy. Thus, blockage or prevention of the activation of these survival signaling pathways may enhance mTOR-targeted cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 2×
“While recent studies have shown encouraging results that the rapalog CCI-779 or RAD001 improved overall survival among patients with metastatic renal-cell carcinoma [19-21], in most other tumor-types, the single-agent activity of rapalogs has been modest, at best [22-24].”
ResultDefining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“It plays a central role in regulating cell growth, proliferation and survival, in part by regulation of translation initiation, primarily through interactions with other proteins such as raptor (forming mTOR complex 1, mTORC1) and rictor (forming mTOR complex 2, mTORC2) [2-4].”
BackgroundThoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381 · cited 9×
“Thus, it is plausible to speculate that blockage of PI3K-dependent activation of these survival signaling pathways will augment rapalogs’ anticancer efficacy.”
BackgroundInfluentialPhosphorylation and Functional Inactivation of TSC2 by Erk
Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268 · cited 2×
“2 Rapalogs combined with MAKP/ERK/RSK inhibitors Recent studies have suggested that MAPK/ERK/RSK signaling functions upstream of and activates mTORC1 signaling [42,44].”
BackgroundPRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236 · cited 1×
“Several recent studies have revealed that PRAS40 is a novel mTORC1-binding partner that mediates Akt signals to mTOR1 [35-37].”
BackgroundPeterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202
Cited by
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Demetri, G. D., Chawla, S. P., Ray-Coquard, I., Le Cesne, A., Staddon, A. P., Milhem, M. M., Penel, N., Riedel, R. F., Bui-Nguyen, B., Cranmer, L. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5766 · Cited by 245
A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs
Shin, H.-C., Alani, A. W. G., Cho, H., Bae, Y., Kolesar, J. M., & Kwon, G. S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2000549 · Cited by 126
Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy
de Wilde, R. F., Edil, B. H., Hruban, R. H., & Maitra, A. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.9 · Cited by 122
CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Martínez-Carreres, L., Puyal, J., Leal-Esteban, L. C., Orpinell, M., Castillo-Armengol, J., Giralt, A., Dergai, O., Moret, C., Barquissau, V., Nasrallah, A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0708 · Cited by 43
Metadata
- Authors
- Wang, X., & Sun, S.-Y.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2009-08-20
- Volume
- 13
- Issue
- 10
- Pages
- 1193-1203
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W1964506355
- Cited by
- 58
- References
- 15
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhancing mTOR-targeted cancer therapy. https://app.cochat.ai/papers/10.1517/14728220903225008
- The paper
- Wang, X., & Sun, S.-Y. (2009). Enhancing mTOR-targeted cancer therapy. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728220903225008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.